Sector: Health Care
Director information for DEXCOM INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Bridgette Heller | Director; Executive Vice President and President of Nutricia, the Specialized Nutrition Division of Danone | 64 | ["Significant executive leadership experience in consumer healthcare","Global technology and manufacturing experience in scaling organizations"] | [] | 2026 |
| Dr. Euan Ashley | Director; Chair of the Department of Medicine | 54 | ["Extensive executive leadership in academic medicine and biotechnology","Expertise in medical technology, genomics, and healthcare innovation","Board experience in global pharmaceutical and biotechnology companies"] | ["Compensation Committee","Nominating and Governance Committee","Technology Committee"] | 2026 |
| Jacob Leach | Director, President and Chief Executive Officer; President and CEO | 48 | ["Over 20 years of experience in the continuous glucose monitoring industry","Leadership in glucose biosensing innovation","Extensive executive and operational leadership at Dexcom"] | ["Executive Committee member for the San Diego Economic Development Corporation"] | 2026 |
| Kevin Sayer | Executive Chairman of the Board; Executive Chair of the Board; Director | 68 | ["Executive oversight of strategy and operations","Significant biosensing and diabetes industry experience"] | [] | 2026 |
| Kyle Malady | Director; Executive Vice President and CEO of Verizon Business; Chair | 59 | ["Executive leadership roles across Verizon","Deep technical expertise in network technology and infrastructure"] | ["Chairman of CTIA","President’s National Security Telecommunications Advisory Council (NSTAC)","Technology Committee"] | 2026 |
| Mark Foletta | Lead Independent Director; Chair | 65 | ["Former Executive Vice President and Chief Financial Officer of Tocagen, Inc. from 2017 to 2020","Former Senior Vice President and Chief Financial Officer of Amylin Pharmaceuticals until its acquisition by Bristol Myers Squibb from 2000 to 2012","More than two decades of financial leadership in healthcare","Deep expertise in audit oversight, capital allocation, and financial strategy","Audit and financial leadership experience at public healthcare companies","Public company board experience","Member of the Corporate Directors Forum","B.A. in Business Economics, UC Santa Barbara","audit committee financial expert","financial qualifications"] | ["Audit Committee"] | 2026 |
| Nicholas Augustinos | Director; President and CEO; Chair | 67 | ["Business development","managerial","technology leadership","healthcare industry experience","Audit and financial leadership experience","Public company board experience"] | ["Technology","Audit","Governance","Investment"] | 2026 |
| Renée Galá | Director; President and Chief Executive Officer | 54 | ["executive leadership experience with oversight of corporate strategy and global operations","public company financial leadership in the life sciences industry"] | ["Audit Committee","Compensation Committee"] | 2026 |
| Richard Collins | Director; Chief Executive Officer | 69 | ["Executive leadership in healthcare insurance and administration","Corporate governance and risk management"] | ["Audit Committee","Compensation Committee"] | 2026 |
| Rick Osterloh | Director; Senior Vice President, Platform & Devices at Google | 53 | ["Executive leadership of complex, global product organizations","Consumer hardware and ecosystem strategy","Strategic transactions and integrations"] | ["Cybersecurity/Technology","Compensation","Technology Committee"] | 2026 |
| Rick Osterloh(1) | Director | 53 | [] | ["Audit Committee","Compensation Committee"] | 2026 |
| Rimma Driscoll | Director; EVP and Head of Global Strategy, Portfolio Marketing and Business Development | 53 | ["More than two decades of global executive leadership spanning strategy, global business development, M&A, global marketing, innovation, commercial operations, and strategic alliances","Executive leadership of diverse, multinational teams to achieve corporate strategy for long-term growth","Business development and mergers and acquisitions, including divestitures, joint ventures and collaborations","Healthcare, pharma and consumer products experience globally"] | ["Audit Committee","Technology Committee"] | 2026 |
| Steven Altman | Director; Former Vice Chairman of Qualcomm | 64 | ["Executive experience and oversight of corporate strategy and transactions","Technical and operational leadership","Corporate governance and legal","Intellectual property and licensing strategy"] | ["Audit Committee","Compensation Committee"] | 2026 |
